P2.01-103 Real-World Treatment Patterns and Survival in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations


      Mutations in the epidermal growth factor receptor (EGFR) gene have been identified in 10-50% of patients with non-small cell lung cancer (NSCLC), and 2-10% are exon 20 insertion mutations. This study describes real-world characteristics, treatment patterns, and overall survival (OS) of NSCLC patients with EGFR exon 20 insertions.


      Flatiron Health electronic health record data from 1/2011-4/2018 were used for this retrospective study. Treatment-naïve (TN) and relapsed/refractory (RR) patients with advanced/metastatic NSCLC with EGFR exon 20 insertion mutation aged ≥18 years at treatment initiation were included. Patient characteristics were described, and Kaplan-Meier analyses were used to assess OS for TN and RR patients.


      OS of patients with EGFR exon 20 NSCLC remains poor. In TN patients, chemotherapy was the most common treatment, followed by EGFR TKIs. Treatment patterns were more diverse in RR patients. This study demonstrated unmet medical need for patients with NSCLC with EGFR exon 20 insertion mutation.


      Non-Small Cell Lung Cancer, overall survival, EGFR exon 20 insertion